DK2532365T3 - Farmaceutisk sammensætning til behandling og/eller forebyggelse af kræft - Google Patents
Farmaceutisk sammensætning til behandling og/eller forebyggelse af kræft Download PDFInfo
- Publication number
- DK2532365T3 DK2532365T3 DK11739876.8T DK11739876T DK2532365T3 DK 2532365 T3 DK2532365 T3 DK 2532365T3 DK 11739876 T DK11739876 T DK 11739876T DK 2532365 T3 DK2532365 T3 DK 2532365T3
- Authority
- DK
- Denmark
- Prior art keywords
- gin
- ser
- glu
- pro
- ala
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Claims (15)
1. Anti-CAPRIN-1 -antistof eller fragment deraf, som udviser en antitumoraktivitet, hvor antistoffet eller fragmentet binder et polypeptid, som består af aminosyresekvensen, der er repræsenteret af SEQ ID NO: 69 eller 70, som er indeholdt i aminosyresekvensen, der er repræsenteret af SEQ ID NO: 37, eller en aminosyresekvens med 80 % eller mere sekvensidentitet med aminosyresekvensen af SEQ ID NO: 69 eller 70.
2. Antistof eller fragment deraf ifølge krav 1, hvor polypeptidet er et partielt polypeptid af CAPRIN-1, hvor CAPRIN-1 er repræsenteret af en af sekvenserne af SEQ ID NO: 2 til 30 med lige nummer.
3. Antistof eller fragment deraf ifølge krav 1 eller krav 2, som har en cytotok-sisk aktivitet mod en kræftcelle, der udviser et CAPRIN-1-protein.
4. Antistof eller fragment deraf ifølge et af kravene 1 til 3, som omfatter: (i) en tungkæde-variabel region omfattende SEQ ID NO: 40, 41 og 42 og en letkæde-variabel region omfattende SEQ ID NO: 44, 45 og 46; (ii) en tungkæde-variabel region omfattende SEQ ID NO: 48, 49 og 50 og en letkæde-variabel region omfattende SEQ ID NO: 52, 53 og 54; (iii) en tungkæde-variabel region omfattende SEQ ID NO: 56, 57 og 58 og en letkæde-variabel region omfattende SEQ ID NO: 60, 61 og 62; (iv) en tungkæde-variabel region omfattende SEQ ID NO: 73, 74 og 75 og en letkæde-variabel region omfattende SEQ ID NO: 77, 78 og 79; (v) en tungkæde-variabel region omfattende SEQ ID NO: 81,82 og 83 og en letkæde-variabel region omfattende SEQ ID NO: 85, 86 og 87 eller; (vi) en tungkæde-variabel region omfattende SEQ ID NO: 89, 90 og 91 og en letkæde-variabel region omfattende SEQ ID NO:93, 94 og 95.
5. Antistof eller fragment deraf ifølge et af kravene 1 til 4, hvor antistoffet eller fragmentet deraf er monoklonalt.
6. Antistof eller fragment deraf ifølge et af kravene 1 til 3, hvor antistoffet eller fragmentet deraf er polyklonalt.
7. Antistof eller fragment deraf ifølge et af kravene 1 til 5, som er et humant antistof, humaniseret antistof, kimærisk antistof, enkeltkædet antistof eller specifikt antistof.
8. Farmaceutisk sammensætning omfattende antistoffet eller fragmentet deraf ifølge et af de foregående krav som et aktivstof.
9. Farmaceutisk sammensætning ifølge krav 8, yderligere omfattende et antitumormiddel.
10. Farmaceutisk kombination, som omfatter den farmaceutiske sammensætning ifølge krav 8 og en farmaceutisk sammensætning, som indeholder et antitumormiddel.
11. Antistof eller fragment deraf ifølge et af kravene 1 til 7, farmaceutisk sammensætning ifølge krav 8 eller krav 9 eller farmaceutisk kombination ifølge krav 10 til anvendelse som et medikament.
12. Antistof eller fragment deraf ifølge et af kravene 1 til 7, farmaceutisk sammensætning ifølge krav 8 eller krav 9 eller farmaceutisk kombination ifølge krav 10 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af kræft.
13. Antistof, fragment eller farmaceutisk sammensætning til anvendelse ifølge krav 12, hvor fremgangsmåden omfatter indgivelse af antistoffet eller fragmentet deraf ifølge et af kravene 1 til 7 eller den farmaceutiske sammensætning ifølge krav 8 og et antitumormiddel til et individ.
14. Antitumormiddel til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af kræft, hvor fremgangsmåden omfatter indgivelse af antitumormidlet og et antistof eller fragment deraf ifølge et af kravene 1 til 7 eller den farmaceutiske sammensætning ifølge krav 8 til et individ.
15. Antistof, fragment, farmaceutisk sammensætning, farmaceutisk kombination eller antitumormiddel til anvendelse ifølge et af kravene 12 til 14, hvor kræften er brystkræft, hjernetumor, leukæmi, lymfom, lungekræft, mastocytom, nyrekræft, livmoderhalskræft, blærekræft, spiserørskræft, ma-vekræft eller kolorektalkræft.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010023451 | 2010-02-04 | ||
PCT/JP2011/052403 WO2011096528A1 (ja) | 2010-02-04 | 2011-02-04 | 癌の治療及び/又は予防用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2532365T3 true DK2532365T3 (da) | 2016-08-15 |
Family
ID=44355522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11739876.8T DK2532365T3 (da) | 2010-02-04 | 2011-02-04 | Farmaceutisk sammensætning til behandling og/eller forebyggelse af kræft |
Country Status (15)
Country | Link |
---|---|
US (1) | US9115200B2 (da) |
EP (1) | EP2532365B1 (da) |
JP (1) | JP5742714B2 (da) |
KR (1) | KR101842893B1 (da) |
CN (1) | CN102821788B (da) |
BR (1) | BR112012018947B8 (da) |
CA (1) | CA2788715C (da) |
DK (1) | DK2532365T3 (da) |
ES (1) | ES2583627T3 (da) |
HU (1) | HUE030103T2 (da) |
MX (1) | MX340014B (da) |
PL (1) | PL2532365T3 (da) |
PT (1) | PT2532365T (da) |
RU (1) | RU2607366C2 (da) |
WO (1) | WO2011096528A1 (da) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2519089C2 (ru) | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
AU2009278386B2 (en) | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
PL2532743T3 (pl) | 2010-02-04 | 2015-09-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka |
AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
KR101758117B1 (ko) | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
MX342291B (es) * | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
KR101979208B1 (ko) | 2011-08-04 | 2019-05-16 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
HUE033628T2 (en) | 2011-08-04 | 2017-12-28 | Toray Industries | Method for detecting pancreatic cancer |
CA2844030C (en) | 2011-08-04 | 2019-09-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
CA2844034C (en) | 2011-08-04 | 2019-07-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
IN2014KN01715A (da) | 2012-02-21 | 2015-10-23 | Toray Industries | |
KR102005308B1 (ko) * | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
JP6187258B2 (ja) * | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
RU2632645C2 (ru) | 2012-02-21 | 2017-10-06 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
DK2832366T3 (da) * | 2012-03-30 | 2018-01-22 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af galdeblærecancer |
TR201902972T4 (tr) * | 2012-07-19 | 2019-03-21 | Toray Industries | Kanseri tespit etmek için yöntem. |
US9753038B2 (en) | 2012-07-19 | 2017-09-05 | Toray Industries, Inc. | Method for detecting cancer via measurement of caprin-1 expression level |
JP6447130B2 (ja) | 2013-08-09 | 2019-01-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
BR112018069332A2 (pt) * | 2016-03-28 | 2019-01-22 | Toray Industries | composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
CA3041979A1 (en) * | 2016-10-28 | 2018-05-03 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
EP3777888A4 (en) * | 2018-03-30 | 2021-12-01 | Toray Industries, Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER |
KR20210128443A (ko) | 2019-02-15 | 2021-10-26 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6 항체 및 이의 용도 |
CN113661175A (zh) * | 2019-02-15 | 2021-11-16 | 整体分子公司 | 包含共同轻链的抗体及其用途 |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CA3175279A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2021182571A1 (da) | 2020-03-12 | 2021-09-16 | ||
EP4119159A4 (en) | 2020-03-12 | 2024-03-27 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
US20230129035A1 (en) | 2020-03-12 | 2023-04-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
US11768197B1 (en) * | 2021-06-19 | 2023-09-26 | Eggschain, Inc. | Rapid fertility and health indicator |
AU2022296193A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
KR20240024803A (ko) | 2021-06-23 | 2024-02-26 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
AU2022319362A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
WO2023008461A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
ES2364266T3 (es) | 1998-04-03 | 2011-08-30 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado. |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
KR20070112860A (ko) | 1998-07-14 | 2007-11-27 | 코릭사 코포레이션 | 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법 |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
WO2000060077A2 (en) | 1999-04-02 | 2000-10-12 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
BR122014028365B8 (pt) * | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
PL366626A1 (en) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
CA2508763C (en) | 2001-05-11 | 2012-01-24 | Kirin Beer Kabushiki Kaisha | Human antibody producing mouse and method for producing human antibody using the same |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
EP2314676A1 (en) | 2002-11-26 | 2011-04-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
AU2004235382A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing AML and MDS differential gene expression |
JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
CA2553826A1 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
JP4734319B2 (ja) | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
RU2429245C2 (ru) | 2004-03-30 | 2011-09-20 | Глаксо Груп Лимитед | Иммуноглобулины |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
US7858324B2 (en) | 2005-02-18 | 2010-12-28 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
KR101310000B1 (ko) | 2005-03-11 | 2013-09-25 | 싸이퍼젠 바이오시스템즈, 인코포레이티드 | 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
CA2642342A1 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
JP2010023451A (ja) | 2008-07-24 | 2010-02-04 | Konica Minolta Business Technologies Inc | 画像形成装置、画像形成方法および画像形成プログラム |
AU2009278386B2 (en) | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
RU2519089C2 (ru) | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
KR101669827B1 (ko) | 2008-08-05 | 2016-10-27 | 도레이 카부시키가이샤 | 면역 유도제 |
PT2467401T (pt) | 2009-08-19 | 2017-04-26 | Merck Patent Gmbh | Anticorpos para a deteção de complexos de integrina em material ffpe |
CA2773240C (en) | 2009-09-22 | 2015-11-10 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
EP2325848B1 (en) | 2009-11-11 | 2017-07-19 | Samsung Electronics Co., Ltd. | Conductive paste and solar cell |
JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
KR101758117B1 (ko) | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
PL2532743T3 (pl) | 2010-02-04 | 2015-09-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
KR101979208B1 (ko) | 2011-08-04 | 2019-05-16 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
HUE033628T2 (en) | 2011-08-04 | 2017-12-28 | Toray Industries | Method for detecting pancreatic cancer |
DK2832366T3 (da) | 2012-03-30 | 2018-01-22 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af galdeblærecancer |
US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
-
2011
- 2011-02-04 CN CN201180017346.7A patent/CN102821788B/zh active Active
- 2011-02-04 DK DK11739876.8T patent/DK2532365T3/da active
- 2011-02-04 BR BR112012018947A patent/BR112012018947B8/pt active IP Right Grant
- 2011-02-04 MX MX2012008999A patent/MX340014B/es active IP Right Grant
- 2011-02-04 CA CA2788715A patent/CA2788715C/en active Active
- 2011-02-04 PL PL11739876.8T patent/PL2532365T3/pl unknown
- 2011-02-04 ES ES11739876.8T patent/ES2583627T3/es active Active
- 2011-02-04 US US13/576,969 patent/US9115200B2/en active Active
- 2011-02-04 PT PT117398768T patent/PT2532365T/pt unknown
- 2011-02-04 HU HUE11739876A patent/HUE030103T2/en unknown
- 2011-02-04 EP EP11739876.8A patent/EP2532365B1/en active Active
- 2011-02-04 RU RU2012137498A patent/RU2607366C2/ru active
- 2011-02-04 WO PCT/JP2011/052403 patent/WO2011096528A1/ja active Application Filing
- 2011-02-04 KR KR1020127022734A patent/KR101842893B1/ko active IP Right Grant
- 2011-02-04 JP JP2011510207A patent/JP5742714B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2532365A4 (en) | 2013-12-04 |
JP5742714B2 (ja) | 2015-07-01 |
EP2532365B1 (en) | 2016-05-04 |
MX340014B (es) | 2016-06-22 |
PT2532365T (pt) | 2016-07-28 |
PL2532365T3 (pl) | 2016-12-30 |
HUE030103T2 (en) | 2017-04-28 |
BR112012018947B8 (pt) | 2020-06-02 |
US20120301476A1 (en) | 2012-11-29 |
MX2012008999A (es) | 2012-08-31 |
BR112012018947A2 (pt) | 2017-06-27 |
WO2011096528A1 (ja) | 2011-08-11 |
CN102821788B (zh) | 2016-11-16 |
CA2788715A1 (en) | 2011-08-11 |
BR112012018947B1 (pt) | 2020-04-28 |
RU2607366C2 (ru) | 2017-01-10 |
AU2011211693A1 (en) | 2012-08-23 |
ES2583627T3 (es) | 2016-09-21 |
JPWO2011096528A1 (ja) | 2013-06-13 |
KR101842893B1 (ko) | 2018-03-28 |
KR20120123500A (ko) | 2012-11-08 |
RU2012137498A (ru) | 2014-03-10 |
EP2532365A1 (en) | 2012-12-12 |
US9115200B2 (en) | 2015-08-25 |
CA2788715C (en) | 2021-06-08 |
BR112012018947A8 (pt) | 2017-12-19 |
CN102821788A (zh) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2532365T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af kræft | |
DK2532364T3 (da) | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af kræft | |
DK2532367T3 (da) | Farmaceutisk middel til behandling og/eller forebyggelse af cancer | |
CA2788718C (en) | Caprin-1 antibody for treating and/or preventing cancer | |
CA2788547C (en) | Pharmaceutical composition for treating and/or preventing cancer | |
CA2788716C (en) | Pharmaceutical composition for treating and/or preventing cancer | |
DK2740489T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af pancreascancer | |
CA2733223C (en) | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers | |
AU2013223143B2 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
DK2740798T3 (da) | Lægemiddelsammensætning til cancerbehandling og/eller forebyggelse | |
DK2740796T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
HUE030137T2 (en) | Pharmaceutical preparation for the treatment and / or prevention of cancer |